KP104

DRUG4 trials

Sponsors

Kira Pharmacenticals (US), LLC.

Conditions

GlomerulonephritisParoxysmal Nocturnal HemoglobinuriaSystemic Lupus Erythematosus

Phase 1

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

CompletedNCT05490017

Kira Pharmacenticals (US), LLC.Paroxysmal Nocturnal Hemoglobinuria

Start: 2020-12-30End: 2022-09-02Updated: 2023-03-01

Phase 2

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

Active, not recruitingNCT05476887

Kira Pharmacenticals (US), LLC.Paroxysmal Nocturnal Hemoglobinuria

Start: 2022-11-25End: 2025-02-28Updated: 2024-10-28

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

Not yet recruitingNCT05504187

Kira Pharmacenticals (US), LLC.Systemic Lupus Erythematosus

Start: 2025-03-31End: 2027-04-30Target: 24Updated: 2024-10-28

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Not yet recruitingNCT05517980

Kira Pharmacenticals (US), LLC.Glomerulonephritis

Start: 2025-03-31End: 2027-04-30Target: 52Updated: 2024-10-28

Related Papers

KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.

Blood2025-11-03

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Blood2024-11-053 citations

KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients

Blood2023-11-025 citations

Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria

Blood2022-11-151 citations